09:58 AM EST, 11/19/2025 (MT Newswires) -- Protara Therapeutics ( TARA ) said Wednesday that its ongoing mid-stage open-label trial, which is evaluating intracystic injection of its investigational therapy TARA-002 in pediatric patients with macrocystic and mixed cystic lymphatic malformations, achieved clinical success.

All patients who completed the eight-week response assessment achieved clinical success, and the therapy demonstrated favorable safety and tolerability profile with no serious adverse events reported, the company said.

The company's shares were down 8% in recent trading on Wednesday.

Price: 6.30, Change: -0.45, Percent Change: -6.67